Co-Author, CD90/THY1 is overexpressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker
Co-Author, Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality
The Journal of Urology
Co-Author, Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence
Clinical Cancer Research
Co-Author, Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients.
Co Author,Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence.
The Journal of Urology
Co Author, PCA3: a molecular urine assay for predicting prostate biopsy outcome.
The Journal of Urology
Co Author, Factors that predict treatment choice and satisfaction with the decision in men with localized prostate cancer.
Clinical Genitourinary Cancer
Co Author, Two-year outcome of unilateral sural nerve interposition graft after radical prostatectomy.
A multiplex assay to measure RNA transcripts of prostate cancer in urine.
PLoS ONE., 7(9):e45656 (2012)
The Personal Patient Profile-Prostate decision support for men with localized prostate cancer: A multi-center randomized trial.
Urol. Oncol., Dec (2011)
Development of an ELISA to detect the secreted prostate cancer biomarker AGR2 in voided urine.
Prostate., Jun;72(9):1023-34 (2012)
Development and evaluation of the personal patient profile-prostate (P3P), a Web-based decision support system for men newly diagnosed with localized prostate cancer.
J. Med. Internet Res., 12(4):e67 (2010)
J. Urol., Nov;184(5):1952 (2010)
CD90/THY1 is overexpressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker.
Mod. Pathol., Oct;23(10):1346-56 (2010)
Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality.
J. Urol., Jun;183(6):2213-8 (2010)
"It's not like I can change my mind later": reversibility and decision timing in prostate cancer treatment decision-making.
Patient Educ Couns., Nov;77(2):302-7 (2009)
Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence.
Clin. Cancer Res., Jan;15(2):677-83 (2009)
Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients.
Cancer Res., Jul;68(14):5599-608 (2008)
Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence.
J. Urol., May;179(5):1775-9 (2008)
PCA3: a molecular urine assay for predicting prostate biopsy outcome.
J. Urol., Apr;179(4):1587-92 (2008)
Point: open radical prostatectomy should not be abandoned.
J Natl Compr Canc Netw., Aug;5(7):685-8 (2007)
The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: a comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer.
Urol. Oncol., 25(3):214-20 (2007 May-Jun)
PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.
Urology., Mar;69(3):532-5 (2007)
Factors that predict treatment choice and satisfaction with the decision in men with localized prostate cancer.
Clin Genitourin Cancer., Dec;5(3):219-26 (2006)
Two-year outcome of unilateral sural nerve interposition graft after radical prostatectomy.
Urology., Dec;68(6):1290-4 (2006)
Improved prostate cancer detection with anterior apical prostate biopsies.
Urol. Oncol., 24(6):492-5 (2006 Nov-Dec)
Actual use and perceived usefulness of a web-based, decision support program for men with prostate cancer.
Stud Health Technol Inform., 122:781-2 (2006)
Telomerase activity in disseminated prostate cancer cells.
BJU Int., Jun;97(6):1309-13 (2006)
Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer.
Clin. Cancer Res., Feb;10(4):1306-11 (2004)
Treatment decision-making by men with localized prostate cancer: the influence of personal factors.
Urol. Oncol., 21(2):93-100 (2003 Mar-Apr)
Cancer Metastasis Rev., 21(2):125-9 (2002)
Serum percent free prostate-specific antigen in metastatic prostate cancer.
Urology., Sep;52(3):366-71 (1998)
Transition zone prostate specific antigen density: lack of use in prediction of prostatic carcinoma.
J. Urol., Jul;160(1):77-81; discussion 81-2 (1998)
The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and followup of patients with prostate cancer.
J. Urol., Apr;159(4):1134-8 (1998)
Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-GuÃ©rin.
Urology., Feb;51(2):226-31 (1998)
Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group.
Urology., Dec;50(6):882-7 (1997)
Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay.
Urology., Oct;50(4):573-9 (1997)
Cell-cell interaction in prostate gene regulation and cytodifferentiation.
Proc. Natl. Acad. Sci. U.S.A., Sep;94(20):10705-10 (1997)
Improved detection of recurrent bladder cancer using the Bard BTA stat Test.
Urology., Sep;50(3):349-53 (1997)
Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages.
Urology., Aug;50(2):184-8 (1997)
Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate.
Clin. Cancer Res., Feb;3(2):249-56 (1997)
Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration.
Int. J. Cancer., Sep;67(6):785-90 (1996)
Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23.
Clin. Cancer Res., Jun;2(6):1039-48 (1996)
Repeat prostate needle biopsy: who needs it?
J. Urol., May;153(5):1496-8 (1995)
Endocrinol. Metab. Clin. North Am., Dec;23(4):809-24 (1994)
The significance of isoechoic prostatic carcinoma.
J. Urol., Dec;152(6 Pt 2):2304-7 (1994)
Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography.
J. Urol., Nov;152(5 Pt 1):1520-5 (1994)
PSA in benign prostatic hyperplasia and prostatic intraepithelial neoplasia.
Urol. Clin. North Am., Nov;20(4):621-5 (1993)
The inability of prostate specific antigen index to enhance the predictive the value of prostate specific antigen in the diagnosis of prostatic carcinoma.
J. Urol., Aug;150(2 Pt 1):369-73 (1993)
Flow cytometric analysis of small renal tumors.
J. Urol., Dec;148(6):1774-7 (1992)